ArticleFrontiers in cardiovascular medicine2025
Venous thromboembolism prophylaxis practices in hematology/oncology patients admitted to neurological intensive care units.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pulmonary Embolism in Hematologic Malignancies: Predictive Value of the D-Dimer/Albumin Ratio and Proposal of the Hema-PE Score.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Venous thromboembolism (VTE) presents a significant challenge for neurocritically ill patients with cancer due to the combined risks of thrombosis and bleeding. This study aimed to describe VTE prophylaxis practices among this high-risk population. Methods: This is a retrospective cohort study at a tertiary teaching hospital. Data were obtained for all patients admitted with neurocritical illness with a history of either solid tumors or hematological malignancies. The main outcome was the incidence of bleeding events in the neurocritical care unit (NCCU) using the International Society on Thrombosis and Haemostasis (ISTH) criteria. Other secondary outcomes were the incidence of thrombotic events, NCCU length of stay, and in-hospital mortality. Results: Out of the 168 patients screened, 43 patients were included, of which 38 patients (88.3%) had solid tumors, and 5 patients (11.6%) had hematologic malignancies. The majority of patients (81.3%) received chemical VTE prophylaxis during hospitalization. The incidence of major bleeding events was reported in 8 patients (21%) with solid tumors and one patient (20%) with hematologic malignancies, with no cases of thrombosis during hospitalization. Compared to the literature, the incidence of major bleeding events in our study is lower than indicated by a previous report on high bleeding risks in similar patient populations. The median duration of hospital stay was five days in the NCCU and 17 days in the hospital, with a 30-day mortality rate of 14%. Conclusion: Our study highlights the complexity of managing VTE prophylaxis in neurocritically ill cancer patients, emphasizing the need for a careful risk-benefit assessment. The absence of thrombotic events suggests effectiveness; however, bleeding risks warrant caution. These findings underscore the importance of individualized care and highlight the need for further research to refine prophylaxis protocols, thereby ensuring both safety and efficacy in this high-risk group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.